Core Viewpoint - Unimed Pharmaceutical has reported a significant loss, with its major subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., contributing 60% of its revenue, now facing production suspension due to regulatory issues [1][2]. Group 1: Company Performance - Unimed Pharmaceutical's stock price dropped to 7.42 yuan, a decrease of 9.95%, resulting in a market capitalization of 4.895 billion yuan following the announcement of the subsidiary's production halt [3]. - Tianjin Unimed's revenue for 2024 was 217 million yuan, with a net profit loss of 14 million yuan, highlighting its critical role in Unimed's overall financial performance [2][5]. - The company's interferon α2b spray, a key product, has been suspended from procurement by multiple regions due to quality issues, further impacting revenue [4][5]. Group 2: Regulatory and Operational Challenges - The Tianjin Municipal Drug Administration has mandated a production and sales suspension for Tianjin Unimed, requiring the completion of rectification and inspection before resuming operations [1][3]. - Unimed Pharmaceutical has initiated a self-inspection process following a quality control failure reported by the Shanghai Drug Administration, which found that a batch of the interferon α2b spray did not meet biological activity standards [4][5]. - If Tianjin Unimed cannot resume production within three months, Unimed Pharmaceutical may face additional risk warnings under the Shenzhen Stock Exchange regulations [2]. Group 3: Financial Implications - The interferon business accounted for 79.52%, 70.56%, and 60.09% of Unimed's revenue from 2022 to 2024, indicating its diminishing but still significant contribution to the company's financial health [5]. - Despite the high gross margin of 79.92% for the interferon products in 2024, Unimed has struggled with profitability, reporting a historical loss of 332 million yuan in 2023 [5].